Clinical Study
Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study
Table 3
Patients treatment.
| | Patient | Age | Diagnosis | Conditioning regimen | MMSCs infusion | GVHD prophylaxis | GVHD stage (days after allo-HSCT) | Chronic GVHD | | Days after allo-HSCT | Passage number (P) | Dose per kg | Cryopreservation |
| | First group (1) standard GVHD prophylaxis | | KO | 38 | CML | MAC | | CSA + Mtx + pr | II (15) | Yes | | IV | 27 | ALL | MAC | | CSA + Mtx+ | II (62) | Yes | | TB | 19 | AML | MAC | | CSA + Mtx+ | II(20) | Yes | | CT | 59 | AML | RIC1 | | CSA + Mtx + MM | IIII–IV (100) | Yes | | SV | 25 | AML | MAC | | CSA + Mtx+ | No | No | | ZL | 34 | CML | MAC | | CSA + Mtx + pr | No | No | | RA | 19 | ALL | MAC | | CSA + Mtx+ | I (23) | No | | KL | 38 | MDS | MAC | | CSA + Mtx+ | No | No | | AD | 38 | AML | MAC | | CSA + Mtx + MM + pr | No | No | | SO | 24 | AML | MAC | | CSA + Mtx+ | I (26) | No | | SE | 51 | AML | RIC2 | | CSA + Mtx+ | II (39) | Yes | | SI | 20 | AML | MAC | | CSA + Mtx | II (10) | Yes | | ZC | 24 | CML | MAC | | CSA + Mtx | No | No | | RA | 31 | AML | MAC | | CSA + Mtx | I (36) | No | | GN | 60 | AML | RIC2 | | CSA + Mtx | No | No | | GJ | 24 | MDS | RIC2 | | CSA + Mtx | No | No | | SN | 36 | ALL | MAC | | CSA + Mtx | I (19) | No | | PE | 22 | CLL | MAC | | CSA + Mtx | No | No |
| | Second group (2) standard GVHD prophylaxis + MMSCs |
| | AN | 34 | AML | MAC | +31 | P2 | 1 | No | CSA + Mtx | No | Yes | | BT | 20 | CML | MAC | +28 | P1 | 1,25 | Yes | CSA + Mtx + pr | No | No | | KA | 22 | ALL | MAC | +29 | P1 | 1,1 | Yes | CSA + Mtx | No | No | | PS | 29 | AML | MAC | +31 | P0 + P1 | 1 | No | CSA + Mtx | No | No | | PN | 46 | AML | MAC | +54 | P3 | 1,08 | Yes | CSA + Mtx | No | No | | KS | 37 | MDS | RIC1 | +28 | P1 | 1,1 | No | CSA + Mtx + MM | I (21) | No | | SE | 54 | AML | RIC1 | +50 | P3 | 1,05 | No | CSA + Mtx + MM | No | No | | RS | 47 | MDS | RIC1 | +34 | P1 | 0,93 | Yes | CSA + Mtx + MM | No | Yes | | CA | 44 | AML | MAC | +32 | P1 | 1,18 | Yes | CSA + Mtx | No | No | | TM | 28 | AML | MAC | +28 | P2 | 1,05 | Yes | CSA + Mtx | No | No | | IL | 63 | AML | RIC1 | +25 | P1 | 0,9 | No | CSA + Mtx + MM | No | No | | CM | 50 | AML | RIC1 | +26 | P1 | 1,07 | Yes | CSA + Mtx + MM | I (48) | No | | BP | 33 | AML | MAC | +29 | P1 | 1,15 | No | CSA + Mtx | No | Yes | | MK | 33 | AML | MAC | +22 | P1 + P2 | 1,12 | Yes | CSA + Mtx | I (17) | Yes | | FE | 39 | CML | MAC | +24 | P1 + P2 | 1,3 | Yes | CSA + Mtx + pr | I (18) | No | | TV | 40 | CML | MAC | +30 | P1 + P2 | 1,26 | Yes | CSA + Mtx + pr | II (25) | Yes | | AI | 22 | ALL | MAC | +19 | P0 + P1 | 1,25 | No | CSA + Mtx | I (73) | No | | DE | 31 | AML | RIC1 | +28 | P1 | 0,96 | Yes | CSA + Mtx + MM | No | No | | SS | 34 | AML | MAC | +24 | P1 + P2 | 1,39 | Yes | CSA + Mtx | No | No |
|
|
AML: acute myeloid leukemia, MDS: myelodysplastic syndrome, ALL: acute lymphoid leukemia, CML: chronic myeloid leukemia, CLL: chronic lymphoid leukemia, RIC: reduced intensity conditioning ((1) fludarabine phosphate + busulfan + ATG, (2) fludarabine phosphate + BCNU + melphalan + ATG), MAC: myeloablative conditioning, CSA: cyclosporine, Mtx: methotrexate, pr: prednisolone, MM: mycophenolate mofetil.
|
